Viking Therapeutics, Inc. (NASDAQ:VKTX) is among the many 11 Greatest GLP-1 and Weight Loss Shares to Put money into. Viking Therapeutics, Inc. (NASDAQ:VKTX) and CordenPharma have concluded a multi-year manufacturing contract to facilitate the business manufacturing of VK2735, the corporate’s twin GLP-1/GIP agonist for weight problems. The deal ensures a yearly provide of greater than 1 billion oral capsules, 100 million autoinjectors, 100 million vial/syringe models, and several other metric tons of API. Prepayments of $150 million shall be made by the agency by 2028 and utilized to imminent orders. The settlement provides particular capability for each oral and subcutaneous formulations.
michaelheim/Shutterstock.com
Viking Therapeutics, Inc. (NASDAQ:VKTX)’s principal metabolic remedy candidate, VK2735, is being developed as an injectable and oral remedy. Part 3 improvement for the injectable model is scheduled to start out in Q2 2025, whereas the corporate is now finishing a Part 2 VENTURE-Oral trial. The enterprise nonetheless owns international rights to VK2735. CEO Brian Lian famous that CordenPharma’s end-to-end provide functionality and peptide manufacturing expertise are important for rising business demand. Viking Therapeutics, Inc. (NASDAQ:VKTX) anticipates that the product can have standard pharmaceutical margins and have a multibillion-dollar potential. It’s among the many Greatest Weight Loss Shares.
Whereas we acknowledge the potential of VKTX as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back threat. In case you’re in search of an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 10 Excessive-Development EV Shares to Make investments In and 13 Greatest Automobile Shares to Purchase in 2025.
Disclosure. None.
